Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

1.3. Revenue and recurring EBITDA

1.3 Net sales by product

1.3 Net sales by product

 

Actual

Variance

€ million

2020

2019

Actual rates

CER

Cimzia®

1 799

1 712

5%

7%

Vimpat®

1 451

1 322

10%

12%

Keppra® (including Keppra® XR / E Keppra®)

788

770

2%

5%

Neupro®

311

319

-2%

-1%

Briviact®

288

221

31%

33%

Nayzilam®

26

0

N/A

N/A

Evenity®

2

0

N/A

N/A

Established brands

358

440

-19%

-16%

Net sales before hedging

5 023

4 784

5%

7%

Designated hedges reclassified to net sales

29

- 104

>-100%

 

Total net sales

5 052

4 680

8%

7%

Total net sales in 2020 increased to € 5 052 million, 8% higher than last year or +7% at constant exchange rates (CER; +8% at CER and adjusted for divestiture). Net sales before “designated hedging reclassified to net sales” were up by 5% (+7% CER).

The growth in 2020 was driven by the resilient UCB product portfolio - despite the pandemic – driving company growth.

 Two medicines were added to the UCB portfolio:

  • In December 2019, UCB launched Nayzilam® (midazolam) Nasal SprayCIV, the first and only nasal rescue treatment for epilepsy seizure clusters in the U.S.

  • Starting in March 2020, Evenity® (romosozumab) had its first European launches under pandemic conditions for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

Core products

Cimzia® (certolizumab pegol), for patients living with inflammatory TNF mediated diseases, net sales reached € 1 799 million (+5%; +7% CER), driven by continued growth in the U.S. and stable net sales in Europe, reflecting the competitive landscape. Strongest growth contributors were new patient populations in psoriasis and psoriatic arthritis, overcompensating a slight decline by 1% in the largest patient population, rheumatoid arthritis, mainly due to other treatment options.

Vimpat® (lacosamide) continues to reach more and more people living with epilepsy, reflected in strong growth in all regions, despite the pandemic. Net sales went up to € 1 451 million (+10%; +12% CER).

Keppra® (levetiracetam), for patients living with epilepsy, reported net sales of € 788 million (+2%; +5% CER). The continued generic erosion in the U.S. has been compensated by recovery from a local, one-time rebate adjustment in Europe and continued growth in international markets where in Japan the UCB team took over distribution of E Keppra® from partner Otsuka in October.

 Briviact® (brivaracetam) for people living with epilepsy, reached net sales of €  288 million, a plus of 31%, (+33% CER). This is driven by significant growth in all regions Briviact® is available to patients. Briviact® has a different mode of action from Vimpat® and differentiates from Keppra®.

 Neupro® (rotigotine), the patch for Parkinson’s disease and restless legs syndrome, recorded net sales to €  311 million (-2%; -1% CER), almost stable in a competitive market environment.

 Nayzilam® (midazolam) Nasal SprayCIV, the first nasal rescue treatment for epilepsy seizure clusters in the U.S. is successfully launched since December 2019 despite the pandemic and reached net sales of € 26 million.

 Evenity® (romosozumab) had its first European launch in March 2020 for the treatment of severe osteoporosis in post-menopausal women at high risk of fracture and reported net sales of € 2 million, impacted by the pandemic which significantly impedes outreach to new patient populations. Evenity® is being launched successfully globally by Amgen, Astellas and UCB since 2019, with net sales outside Europe reported by the partners.

Established brands

Net sales of established brands went down by 19% to € 358 million, adjusted for divestitures (mainly in Europe) the decline was 13% (-10% CER) , reflecting the maturity of the portfolio and impact by generic competition.

Main part of the portfolio are UCB’s allergy products Zyrtec® (cetirizine, including Zyrtec®-D / Cirrus®) and Xyzal® (levocetirizine), both showed declines due maturity and generic competition.

Designated hedges reclassified to net sales were positive with € 29 million (negative with € 104 million in 2019) reflecting UCB’s realized transactional hedging activities which have to be recognized in the “net sales” line according to IFRS. These are mainly related to the U.S. Dollar, the Japanese Yen, the British Pound and the Swiss Franc.